FDA allows compounders to repackage, combine propofol amid Covid-19
After allowing compounders and outsourcing facilities to compound 13 drugs needed to treat patients on ventilators during the coronavirus disease (Covid-19) public health emergency, the FDA says it will allow compounders to repackage or combine propofol to meet hospitals’ needs.
“FDA has received reports from some hospitals that they are having difficulty obtaining adequate supplies of FDA-approved propofol injectable emulsion (propofol) products, 10 milligram (mg) per milliliter (mL), in the presentations used to support Covid-19 patients who have been sedated and intubated, or for other procedures involved in the care of such patients,” FDA writes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.